ASX:BGT

Bio-Gene Technology Competitors

Add

Compare

Today's Range N/A

50-Day Range

A$0.19

MA: A$0.19▼

A$0.19

52-Week Range N/A

VolumeN/A

Average VolumeN/A

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Bio-Gene Technology (ASX:BGT) Vs. CHV, DDXS, PREV, TNGN, COM, and MYM

Should you be buying BGT stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Bio-Gene Technology, including (CHV) (CHV), (DDXS) (DDXS), (PREV) (PREV), (TNGN) (TNGN), 138267 (COM.TO) (COM), and 17031 (MYM).

Bio-Gene Technology vs. (CHV) Stock

(CHV) (CNSX:CHV) and Bio-Gene Technology (ASX:BGT) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, dividends, earnings and analyst recommendations.

Analyst Recommendations

This is a summary of current ratings for (CHV) and Bio-Gene Technology, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
(CHV)	0	0	0	0	N/A
Bio-Gene Technology	0	0	0	0	N/A

Profitability

This table compares (CHV) and Bio-Gene Technology's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
(CHV)	N/A	N/A	N/A
Bio-Gene Technology	N/A	N/A	N/A

Earnings and Valuation

This table compares (CHV) and Bio-Gene Technology's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
(CHV)	N/A	N/A	N/A	N/A	N/A
Bio-Gene Technology	$82,795.00	0.00	$-2,577,370.00	A($0.02)	N/A

(CHV) has higher earnings, but lower revenue than Bio-Gene Technology.

Summary

Bio-Gene Technology beats (CHV) on 1 of the 1 factors compared between the two stocks.

Bio-Gene Technology vs. (DDXS) Stock

Bio-Gene Technology (ASX:BGT) and (DDXS) (OTCMKTS:DDXS) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

Analyst Recommendations

This is a summary of recent recommendations for Bio-Gene Technology and (DDXS), as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Gene Technology	0	0	0	0	N/A
(DDXS)	0	0	0	0	N/A

Earnings & Valuation

This table compares Bio-Gene Technology and (DDXS)'s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Gene Technology	$82,795.00	0.00	$-2,577,370.00	A($0.02)	N/A
(DDXS)	N/A	N/A	N/A	N/A	N/A

(DDXS) has lower revenue, but higher earnings than Bio-Gene Technology.

Profitability

This table compares Bio-Gene Technology and (DDXS)'s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bio-Gene Technology	N/A	N/A	N/A
(DDXS)	N/A	N/A	N/A

Summary

Bio-Gene Technology beats (DDXS) on 1 of the 1 factors compared between the two stocks.

Bio-Gene Technology vs. (PREV) Stock

Bio-Gene Technology (ASX:BGT) and (PREV) (CNSX:PREV) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

Profitability

This table compares Bio-Gene Technology and (PREV)'s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bio-Gene Technology	N/A	N/A	N/A
(PREV)	N/A	N/A	N/A

Valuation and Earnings

This table compares Bio-Gene Technology and (PREV)'s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Gene Technology	$82,795.00	0.00	$-2,577,370.00	A($0.02)	N/A
(PREV)	N/A	N/A	N/A	N/A	N/A

(PREV) has lower revenue, but higher earnings than Bio-Gene Technology.

Analyst Ratings

This is a summary of current ratings and price targets for Bio-Gene Technology and (PREV), as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Gene Technology	0	0	0	0	N/A
(PREV)	0	0	0	0	N/A

Summary

Bio-Gene Technology beats (PREV) on 1 of the 1 factors compared between the two stocks.

Bio-Gene Technology vs. (TNGN) Stock

Bio-Gene Technology (ASX:BGT) and (TNGN) (OTCMKTS:TNGN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership and risk.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Bio-Gene Technology and (TNGN), as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Gene Technology	0	0	0	0	N/A
(TNGN)	0	0	0	0	N/A

Earnings & Valuation

This table compares Bio-Gene Technology and (TNGN)'s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Gene Technology	$82,795.00	0.00	$-2,577,370.00	A($0.02)	N/A
(TNGN)	N/A	N/A	N/A	N/A	N/A

(TNGN) has lower revenue, but higher earnings than Bio-Gene Technology.

Profitability

This table compares Bio-Gene Technology and (TNGN)'s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bio-Gene Technology	N/A	N/A	N/A
(TNGN)	N/A	N/A	N/A

Summary

Bio-Gene Technology beats (TNGN) on 1 of the 1 factors compared between the two stocks.

Bio-Gene Technology vs. 138267 (COM.TO) Stock

138267 (COM.TO) (TSE:COM) and Bio-Gene Technology (ASX:BGT) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and valuation.

Analyst Recommendations

This is a breakdown of current ratings for 138267 (COM.TO) and Bio-Gene Technology, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
138267 (COM.TO)	0	0	0	0	N/A
Bio-Gene Technology	0	0	0	0	N/A

Earnings and Valuation

This table compares 138267 (COM.TO) and Bio-Gene Technology's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
138267 (COM.TO)	N/A	N/A	N/A	N/A	N/A
Bio-Gene Technology	$82,795.00	0.00	$-2,577,370.00	A($0.02)	N/A

138267 (COM.TO) has higher earnings, but lower revenue than Bio-Gene Technology.

Profitability

This table compares 138267 (COM.TO) and Bio-Gene Technology's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
138267 (COM.TO)	N/A	N/A	N/A
Bio-Gene Technology	N/A	N/A	N/A

Summary

Bio-Gene Technology beats 138267 (COM.TO) on 1 of the 1 factors compared between the two stocks.

Bio-Gene Technology vs. 17031 Stock

17031 (CNSX:MYM) and Bio-Gene Technology (ASX:BGT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.

Analyst Ratings

This is a breakdown of current recommendations and price targets for 17031 and Bio-Gene Technology, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
17031	0	0	0	0	N/A
Bio-Gene Technology	0	0	0	0	N/A

Profitability

This table compares 17031 and Bio-Gene Technology's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
17031	N/A	N/A	N/A
Bio-Gene Technology	N/A	N/A	N/A

Earnings & Valuation

This table compares 17031 and Bio-Gene Technology's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
17031	N/A	N/A	N/A	N/A	N/A
Bio-Gene Technology	$82,795.00	0.00	$-2,577,370.00	A($0.02)	N/A

17031 has higher earnings, but lower revenue than Bio-Gene Technology.

Summary

Bio-Gene Technology beats 17031 on 1 of the 1 factors compared between the two stocks.